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The incidence of melanoma, the most aggressive type of cutaneous malignant tumor, is currently on the rise. Treatment in
advanced stages is still unsuccessful compared with other malignant tumors, thus it is important to indentify the key mechanisms
responsible for melanoma progression and metastasis. Genetic and molecular components, in particular, that are up- or
downregulated in melanoma cells, affect the invasive potential of melanoma. Another possible important cofactor highlighted
by recent studies is chronic stress, involving environmental and psychological factors, which can be an important cofactor in not
only cancer progression in general but also in melanoma spreading. The negative effects of chronic stress have been evaluated
epidemiologically in patients with breast and prostate cancer. In particular, the effects of stress mediators, namely, catecholamines
have been studied on various humanmalignancies, includingmelanoma and have highlighted a significant increase of progression-
related molecules. As such, this could be the starting point for a new approach in the treatment of advanced melanoma, in which
the negative effects of stress are reduced or blocked.
1. Introduction
At present, melanoma remains the most aggressive type of
cutaneous malignant tumor. In contrast to the incidence
of other tumors, the incidence of melanoma continues to
increase, the majority of which is seen in young adults.
Consequently, death attributed to melanoma is higher than
most other solid tumors [1].
Malignant melanoma has had a rapid increase in
incidence in recent years, without being associated with
better therapeutic options. Compared to other malignant
tumors that can be treated effectively even in advanced
stages, metastatic melanoma still has a poor response to
chemotherapy, immunotherapy, and radiation therapy. At
present, surgery in the early stages represents the only
approach to quickly eradicate the disease [2]. It is crucial
moreover to prevent or reduce the factors capable of affecting
melanoma progression and diffusion, due to the intractabil-
ity of advancedmelanoma. To do so, we must understand the
key aspects concerning the mechanisms underlying local and
distant invasion of this malignant tumor.
2. Main Factors Affecting
Melanoma Progression
The progression of melanoma is affected by a series of
genetic and molecular mechanisms. Transition from normal
melanocytes to malignant metastatic cells is the consequence
of up- and downregulation of complex cellular processes [3].
One of themost important and studied invasionmechanisms
of melanoma cells is the expression of various adhesion
membrane molecules.
Physiologically, epidermal melanocytes are connected
with keratinocytes through multiple contacts between the
cells. In this manner, keratinocytes control melanocyte
growth and cell surface receptor expression. Melanoma cells
escape this control mechanism and begin to invade the
dermis through a number of mechanisms implemented by
melanoma cells themselves.
Adhesionmolecules, such as E-cadherin, P-cadherin, and
desmoglein, result in being downregulated in melanoma
cells which can disengage from keratinocytes [3]. Instead,
N-cadherin, Mel-CAM, and zonula occludens protein-1 are
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upregulated on melanoma cells, facilitating interaction with
stromal fibroblasts [4] and endothelial cells and allowing
entry into the vasculature [5]. That is to say, during
melanoma progression, the loss of E-cadherin expression [6]
disrupts normal homeostasis by freeing melanoma cells from
structural and functional regulation by keratinocytes and is
paralleled by a gain in N-cadherin function [4] that mediates
homotypic interaction between melanoma cells, facilitates
gap-junctional formation with fibroblasts and endothelial
cells, and promotes melanoma cell migration and survival
[7].
The integrin family also plays a role in regulating
other processes involved in progression and metastasis of
melanoma. Integrins are adhesion molecules that couple
the extracellular environment to the cytoskeleton, while also
transmitting intracellular signals responsible for an assort-
ment of cellular processes including survival, migration,
invasion, and proliferation [7, 8]. In particular, the integrin
family member αvβ3 [9] seems to be widely expressed
on melanoma cells in the vertical growth phase and is
associated with increased tumor growth in vivo. Thus during
melanomagenesis, melanocytes show increased levels of αvβ3
integrin concomitant with the loss of E-cadherin expression
[10].
Moreover, tissue invasion is mediated by proteinases
specific for interstitial extracellular matrix such as metallo-
proteinases (MMPs), particularly matrix metalloproteinases
MMP-2 and MMP-9. The MMPs belong to a family of
calcium- and zinc-dependent endopeptidase and can digest
a wide range of matrix extracellular molecules. In fact
the MMPs are implicated in tumor cell invasion through
the degradation of interstitial and basement membrane
extracellular matrix. It is this event that represents an
important stage of tumor progression and is demonstrated
principally by a coexpression of MMP-2 and MMP-9 in
invasive and in situ melanoma [11].
Diffusion and progression are further influenced by
autocrine and paracrine production of cytokines [12] such
as, for example, Transforming Growth Factor (TGF) beta,
Hepatocyte Grow Factor (HGF), Fibroblast Growth Fac-
tor (FGF), Vascular Endothelial Growth Factor (VEGF)
A, and Vascular Endothelial Growth Factor (VEGF) C.
These growth factors are very important for melanoma
progression, because they support cell survival and enhance
metastatic potential, creating a microenvironment that pro-
motes growth and tumor expansion [13, 14]. In partic-
ular, VEGF is an essential factor for tumor angiogenesis
that increases the permeability of microvessels, acts as a
selective endothelial cell mitogen, and induces increased
production of other tissue factors and several proteases [11].
These events are confirmed by data that show that malig-
nant melanocytic tumors displayed strong VEGF expres-
sion whereas benign melanocytic proliferations showed no
immunoreactivity for VEGF [11].
Changes in migration, invasion, proliferation, and sur-
vival [7, 8, 11, 13, 14] are responsible for the inva-
sive potential of melanoma, and in vitro studies show
that multiple mechanisms are involved in these processes
besides the above mentioned, and they include extension
of protrusions (induced by actin polymerization) [15, 16],
contraction (a process actin-myosin linked) deadhesion (a
mechanismmediated by actin disassembly [17]), sliding, and
fragmentation of the cell [18–21].
3. Stress and Cancer
Significant evidence exists demonstrating that chronic stress
and cancer progression are connected. To begin with,
stress leads to an important activation in both central and
peripheral nervous systems and increased hormone and
peptide production (particularly neuropeptides and neuro-
transmitters). These events are considered physiological and
adaptive responses in acute stress but are harmful in chronic
stress conditions [22]. Therefore chronic stress, defined as a
complex process including environmental and psychological
factors, can influence not only cellular immune parameters
with a reduction in immune response but can also influence
other biological pathways. Recent studies have thoroughly
investigated these effects, evaluating the effects of stress on
the course of some malignant tumors [22]. Epidemiological
data show that chronic depression due to separation, divorce,
or death of spouse may have an important role in the onset,
progression, and response to breast cancer therapy. In fact,
a US breast cancer study demonstrated that the risk of
developing breast cancer increases if stress conditions and
depression persist for at least six years [23] and that the
mood of the patients seems to be very important in disease
progression. Patients with a negative reaction to cancer
diagnosis have a faster disease progression and a poorer
response to therapy. Conversely, “positive” factors, such as
the presence of social support and an optimistic attitude
toward illness, favor a longer survival [23]. Experimental
stressors have also been found to increase the pathogenesis
of various virus-mediated tumors in animal models, such
as leukemia, lymphoma, liver carcinoma, Kaposi-sarcoma,
cervical cancer, and rectal cancer [24] In hepatocellular
carcinoma, animals were treated with the carcinogen diethyl-
nitrosamine associated with immobilization that increased
both incidence and rate of tumor growth [25], confirming
the aforementioned results.
An additional study on mice by Hasegawa and Saiki
[26] demonstrated the presence of an interrelationship
among psychosocial stress, tumor development, and beta-
adrenergic activation. The application of several stress
paradigms including rotation, social housing conditions,
and restraint enhanced tumor growth of B16 melanoma
implanted in the footpad of syngeneic male mice. It has been
also demonstrated that chronic behavioural stress results in
high levels of tissue catecholamines, greater tumor burden,
and more invasive growth of ovarian carcinoma cells in an
orthotopicmousemodel. Tumors in stressed animals showed
markedly increased vascularization and enhanced expression
of VEGF, MMP-2, and MMP-9; it seems that angiogenic
processes mediate the effects of stress on tumor growth in
vivo [27].
With regard to human cancer, a study by Sood et al.
[28] on human ovarian carcinoma cells has demonstrated
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that chronic behavioural stress and, above all, the neuroen-
docrine corresponding responses can affect ovarian cancer
cell biology, enhancing angiogenesis and tumor growth.
This effect is mediated by catecholamine interaction with
beta2-adrenergic receptors expressed on ovarian tumor cells
that can influence tumor progression by stimulating the
expression of MMPs. It has further been demonstrated
that exposure to epinephrine and norepinephrine increases
ovarian cancer cell invasiveness by 89% to 198%, and these
effects are completely abolished by adrenergic beta-blockers
such as propranolol [28–30]. TheMMPs (particularly MMP-
2 and MMP-9) and VEGF expression has been studied
also in three nasopharyngeal carcinoma human cell lines
as factors that can contribute to tumor development and
aggressiveness under stimulation of catecholamines. Yang
et al. have shown that in nasopharyngeal carcinoma cells
expressing beta2-adrenergic receptor, these hormones induce
the production of all three molecules, which are blocked by
beta-adrenergic antagonists such as propranolol [31].
Recently, Yang and colleagues have studied the possible
role of catecholaminergic stimulation on human multiple
myeloma cells, in order to demonstrate if VEGF is differ-
entially regulated by norepinephrine. The authors have con-
firmed the presence of beta1- and beta2-adrenergic receptors
on three different myeloma cell lines and demonstrated
that norepinephrine was able to enhance the production of
VEGF. These data indicate that angiogenesis is stimulated by
catecholamines also in multiple myeloma and that stress is
an important mechanism in the biology and progression of
various cancers [32].
4. Melanoma and Stress
Melanoma cells also express both alpha- and beta adrenore-
ceptors, which can be activated by catecholamines released
under stress. Shih and Lo in 1993 [33] conducted a study
which pointed that GMM-1 cells (a goldfish melanocytoma
cell line) treated with epinephrine exhibited a rapid expan-
sion. This effect consisted in various changes of cellular
morphology, namely, flattening of cells and extension and
broadening of cellular processes, which suggest that the
effects of various epinephrine agonists and antagonists may
be caused by multiple isoforms of adrenoceptors in goldfish
cells [33].
Scarparo et al. have demonstrated the presence of
low affinity alpha1-adrenoceptors in SK-Mel 23 human
melanoma cells. Alpha1-adrenoceptors are coupled to Gq
protein, and they activate phospholipase C (PLC) and
increase intracellular calcium. When activated by cate-
cholamines they mediate a decrease in cell proliferation
and an increase in tyrosinase activity, with no change of
tyrosinase expression. The administration of an alpha1-
adrenergic agonist such as phenylephrine thereby induces
decreased proliferation and increased tyrosinase activity
while an alpha1-adrenergic antagonist such as prazosine
blocks these activities. It therefore seems that alpha1-
adrenoceptors, expressed by melanoma cells, have a low
affinity for catecholamines and exert a marginal role in
tumor growth and invasion [34, 35].
Recently, Yang et al. [36] investigated the expression of
beta1- and beta2-adrenergic receptors in three cell lines of
human melanoma, C8161, 1174MEL, and Me18105 and the
expression of both adrenoceptors, and analyzed the cellular
response to norepinephrine stimulation. The presence of
beta1- and beta2-adrenoceptors was assessed in primary and
metastatic human melanoma cells by immunohistochem-
istry. Norepinephrine was able to enhance tumor progres-
sion, by stimulating the secretion of factors implicated in
angiogenesis and metastasis [36].
In particular, melanoma cells treated with nore-
pinephrine exhibited an upregulation of VEGF, IL-8, and
IL-6. These three cytokines play proangiogenic, chemotactic,
or autocrine stimulant activity, respectively, and are closely
related with melanoma progression, considering that their
production by melanomatous cells is increased in advanced
tumor stages [14, 36].
These data are of particular interest because they sup-
port the hypothesis that catecholamines, which are typical
stress hormones, can promote the aggressive potential of
melanoma tumor cells through the interaction with specific
receptors. Intervention targeting these receptors or the
production of stress hormones, such as pharmacological
treatment with adrenoceptor-blocking agents or social and
psychological support, may represent a valid approach in
the treatment of advanced melanoma, which is at present an
unresponsive disease [36] and potentially even in early stages
of the disease.
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